Literature DB >> 22592999

Piperlongumine induces rapid depletion of the androgen receptor in human prostate cancer cells.

Konstantin V Golovine1, Peter B Makhov, Ervin Teper, Alexander Kutikov, Daniel Canter, Robert G Uzzo, Vladimir M Kolenko.   

Abstract

BACKGROUND: Androgen receptor (AR) signaling is regarded as the driving force in prostate carcinogenesis, and its modulation represents a logical target for prostate cancer (PC) prevention and treatment. Natural products are the most consistent source of small molecules for drug development. In this study, we investigate the functional impact of piperlongumine (PL), a naturally occurring alkaloid present in the Long pepper (Piper longum), on AR expression in PC cells and delineate its mechanism of action.
METHODS: Expression and transcriptional activity of AR was examined by western blotting and luciferase reporter assay, respectively. CellTiter Blue assay was utilized to quantify cell proliferation. Reactive oxygen species (ROS) generation was examined by staining cells with a ROS indicator CM-H(2) DCFDA, followed by flow cytometry analysis.
RESULTS: The results of our experiments demonstrate that PL rapidly reduces AR protein levels in PC cells via proteasome-mediated ROS-dependent mechanism. Moreover, PL effectively depletes a modified AR lacking the ligand-binding domain, shedding light on a new paradigm in the treatment approach to prostatic carcinoma that expresses mutated constitutively active AR. Importantly, PL effectively depletes AR in PC cells at low micromolar concentrations, while concurrently exerting a significant inhibitory effect on AR transcriptional activity and proliferation of PC cells.
CONCLUSIONS: Our investigation demonstrates for the first time that PL induces rapid depletion of the AR in PC cells. As such, PL may afford novel opportunities for both prevention and treatment of prostatic malignancy.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592999      PMCID: PMC3491117          DOI: 10.1002/pros.22535

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  29 in total

1.  Overexpression of the zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo.

Authors:  Konstantin Golovine; Peter Makhov; Robert G Uzzo; Tavis Shaw; David Kunkle; Vladimir M Kolenko
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

2.  Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator.

Authors:  Cláudia V Pereira; Nuno G Machado; Paulo J Oliveira
Journal:  Toxicol Sci       Date:  2008-07-03       Impact factor: 4.849

Review 3.  Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Authors:  Mary-Ellen Taplin
Journal:  Nat Clin Pract Oncol       Date:  2007-04

4.  Isosilybin B causes androgen receptor degradation in human prostate carcinoma cells via PI3K-Akt-Mdm2-mediated pathway.

Authors:  G Deep; N H Oberlies; D J Kroll; R Agarwal
Journal:  Oncogene       Date:  2008-03-10       Impact factor: 9.867

5.  Suppressive effects of bisphenol A on the proliferation of neural progenitor cells.

Authors:  Keunho Kim; Tae Gen Son; So Jung Kim; Hyung Sik Kim; Tae Sung Kim; Soon Young Han; Jaewon Lee
Journal:  J Toxicol Environ Health A       Date:  2007-08

6.  In vivo growth inhibition of sarcoma 180 by piperlonguminine, an alkaloid amide from the Piper species.

Authors:  Daniel P Bezerra; Cláudia Pessoa; Manoel Odorico de Moraes; Nylane M N de Alencar; Rodney O Mesquita; Michael W Lima; Ana Paula N N Alves; Otília Deusdênia L Pessoa; João Henrique Chaves; Edilberto R Silveira; Letícia V Costa-Lotufo
Journal:  J Appl Toxicol       Date:  2008-07       Impact factor: 3.446

7.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.

Authors:  R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

8.  Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence.

Authors:  Stephen J Libertini; Clifford G Tepper; Veronica Rodriguez; David M Asmuth; Hsing-Jien Kung; Maria Mudryj
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

Review 9.  Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

Authors:  John M Fitzpatrick; John Anderson; Cora N Sternberg; Neil Fleshner; Karim Fizazi; Xavier Rébillard; Luigi Dogliotti; Giario Conti; Ingela Turesson; Nicholas James; Axel Heidenreich; Eduardo Solsona; Vicente Guillem; Daniel Herchenhorn; Judd Moul; Jeroen van Moorselaar; Lance J E Coetzee; Andrew Wilson; Aristotelis Bamias; Ronald De Wit; Michael Chrisofos
Journal:  Crit Rev Oncol Hematol       Date:  2008-08-23       Impact factor: 6.312

Review 10.  Androgen receptor structural and functional elements: role and regulation in prostate cancer.

Authors:  Scott M Dehm; Donald J Tindall
Journal:  Mol Endocrinol       Date:  2007-07-17
View more
  23 in total

1.  Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.

Authors:  Yaroslava Karpova; Chao Wu; Ali Divan; Mark E McDonnell; Elizabeth Hewlett; Peter Makhov; John Gordon; Min Ye; Allen B Reitz; Wayne E Childers; Tomasz Skorski; Vladimir Kolenko; Alexei V Tulin
Journal:  Biochem Pharmacol       Date:  2019-03-15       Impact factor: 5.858

2.  Piperlongumine inhibits atherosclerotic plaque formation and vascular smooth muscle cell proliferation by suppressing PDGF receptor signaling.

Authors:  Dong Ju Son; Soo Yeon Kim; Seong Su Han; Chan Woo Kim; Sandeep Kumar; Byeoung Soo Park; Sung Eun Lee; Yeo Pyo Yun; Hanjoong Jo; Young Hyun Park
Journal:  Biochem Biophys Res Commun       Date:  2012-09-17       Impact factor: 3.575

3.  Piperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cells.

Authors:  Serge Ginzburg; Konstantin V Golovine; Petr B Makhov; Robert G Uzzo; Alexander Kutikov; Vladimir M Kolenko
Journal:  Prostate       Date:  2013-10-22       Impact factor: 4.104

4.  Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma.

Authors:  Konstantin Golovine; Peter Makhov; Sei Naito; Henish Raiyani; Jeffrey Tomaszewski; Reza Mehrazin; Alexei Tulin; Alexander Kutikov; Robert G Uzzo; Vladimir M Kolenko
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  Piperlongumine induces apoptotic and autophagic death of the primary myeloid leukemia cells from patients via activation of ROS-p38/JNK pathways.

Authors:  Xin-xin Xiong; Ju-mei Liu; Xin-yao Qiu; Feng Pan; Shang-bin Yu; Xiao-qian Chen
Journal:  Acta Pharmacol Sin       Date:  2015-01-26       Impact factor: 6.150

6.  The Clinical Potential of Senolytic Drugs.

Authors:  James L Kirkland; Tamara Tchkonia; Yi Zhu; Laura J Niedernhofer; Paul D Robbins
Journal:  J Am Geriatr Soc       Date:  2017-09-04       Impact factor: 5.562

7.  An improved quantitative approach for the assessment of mitochondrial fragmentation in chemoresistant ovarian cancer cells.

Authors:  Lee Farrand; Ji Young Kim; Akechai Im-Aram; Jeong-Yong Suh; Hyong Joo Lee; Benjamin K Tsang
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

8.  Optimization and comprehensive characterization of a faithful tissue culture model of the benign and malignant human prostate.

Authors:  Sophia Lisette Maund; Rosalie Nolley; Donna Mae Peehl
Journal:  Lab Invest       Date:  2013-12-02       Impact factor: 5.662

9.  Piperlongumine promotes autophagy via inhibition of Akt/mTOR signalling and mediates cancer cell death.

Authors:  P Makhov; K Golovine; E Teper; A Kutikov; R Mehrazin; A Corcoran; A Tulin; R G Uzzo; V M Kolenko
Journal:  Br J Cancer       Date:  2014-01-16       Impact factor: 7.640

10.  Piperlongumine inhibits migration and proliferation of castration-resistant prostate cancer cells via triggering persistent DNA damage.

Authors:  Ding-Fang Zhang; Zhi-Chun Yang; Jian-Qiang Chen; Xiang-Xiang Jin; Yin-da Qiu; Xiao-Jing Chen; Hong-Yi Shi; Zhi-Guo Liu; Min-Shan Wang; Guang Liang; Xiao-Hui Zheng
Journal:  BMC Complement Med Ther       Date:  2021-07-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.